Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Radioterapi med redusert dose for behandling av indolent non-Hodgkin-lymfom

6. november 2026 oppdatert av: Mayo Clinic

Redusert dose hypofraksjonert strålebehandling (3Gy x 3 fraksjoner) for indolent non-Hodgkin lymfom (POSEIDON): En flersteds fase 2 randomisert studie

This phase II trial compares the safety, side effects and effectiveness of reduced dose radiation therapy to standard of care dose radiation in treating patients with indolent non-Hodgkin lymphoma. Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill cancer cells and shrink tumors. Standard of care radiation treatment for indolent non-Hodgkin lymphoma is usually delivered in 12 treatments. Studies have shown indolent lymphoma to be sensitive to radiation treatment, however, larger doses have higher rates of toxicities. A reduced radiation dose may be safe, tolerable and/or effective compared to standard of care radiation dose in treating patients with indolent non-Hodgkin lymphoma.

Studieoversikt

Detaljert beskrivelse

PRIMARY OBJECTIVE:

I. To show that the experimental arm [9 gray (Gy) in 3 fractions, 8 Gy in 2 fractions, or 10 Gy in 5 fractions] has significantly reduced acute toxicity (grade ≥ 2 adverse events at least possibly related to radiation treatment within 14 days after the end of radiation treatment [according to Common Terminology Criteria for Adverse Events (CTCAE) version (v)5.0] compared to 24 Gy in 12 fractions.

SECONDARY OBJECTIVES:

I. To evaluate patient reported quality of life. II. To evaluate response rate. III. To evaluate local control rate. IV. To evaluate relapse-free survival.

EXPLORATORY OBJECTIVES:

I. Financial toxicity will be assessed at the end of radiation treatment. II. Financial health care expenditure will be assessed at the end of radiation treatment III. Late toxicity.

CORRELATIVE RESEARCH OBJECTIVES:

I. Biopsies of enrolled patients will be evaluated for pathological assessment of cellular and genetic mutations to correlate them with disease local relapse and radiation resistance.

II. Patients will have their baseline positron emission tomography (PET)/computed tomography (CT) scan undergo auto-segmentation to calculate the functional imaging 18-fluoro-deoxyglucose (FDG) metabolic tumor volume (MTV), total lesions glycolysis (TLG) and maximum standardized uptake volume (SUVmax) of the sites to be treated with involved-site radiation therapy (ISRT) using MIMvista platform to correlate it with disease local relapse and treatment response.

OUTLINE: Patients are randomized to 1 of 2 arms.

ARM I: Patients undergo reduced dose ISRT once daily (QD) over 3, 2, or 5 treatment fractions. Patients also undergo CT or PET/CT throughout the study. Patients may additionally undergo endoscopy during screening and during follow up.

ARM II: Patients undergo standard of care (SOC) radiation therapy QD over 12 treatment fractions. Patients also undergo CT or PET/CT throughout the study. Patients may additionally undergo endoscopy during screening and during follow up.

After completion of study treatment, patients are followed up at days 7 and 14, months 3 and 6, and then every 6 months for up to 2 years post-radiation therapy.

Studietype

Intervensjonell

Registrering (Antatt)

112

Fase

  • Fase 2

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studiesteder

    • Arizona
      • Scottsdale, Arizona, Forente stater, 85259
        • Rekruttering
        • Mayo Clinic in Arizona
        • Ta kontakt med:
        • Hovedetterforsker:
          • William G. Rule, MD
    • Florida
      • Jacksonville, Florida, Forente stater, 32224-9980
        • Rekruttering
        • Mayo Clinic in Florida
        • Ta kontakt med:
        • Hovedetterforsker:
          • Brad S. Hoppe, MD, MPH
    • Minnesota
      • Albert Lea, Minnesota, Forente stater, 56007
        • Rekruttering
        • Mayo Clinic Health System in Albert Lea
        • Ta kontakt med:
        • Hovedetterforsker:
          • John Yeakel, MD
      • Mankato, Minnesota, Forente stater, 56001
        • Tilbaketrukket
        • Mayo Clinic Health System - Mankato
      • Rochester, Minnesota, Forente stater, 55905
        • Rekruttering
        • Mayo Clinic in Rochester
        • Ta kontakt med:
        • Hovedetterforsker:
          • Scott C. Lester, MD
    • Wisconsin
      • Eau Claire, Wisconsin, Forente stater, 54701
        • Rekruttering
        • Mayo Clinic Health System-Eau Claire Clinic
        • Ta kontakt med:
        • Hovedetterforsker:
          • Now Bahar Alam, MD
      • La Crosse, Wisconsin, Forente stater, 54601
        • Rekruttering
        • Mayo Clinic Health System-Franciscan Healthcare
        • Ta kontakt med:
        • Hovedetterforsker:
          • Abigail L. Stockham, MD

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • Age ≥ 18 years

  • Histological confirmation of indolent B-cell lymphoma that can include any of the following:

    • Follicular lymphoma (grade 1 or 2 or 3A)
    • Marginal zone lymphoma (nodal or extranodal)
    • Follicle center lymphoma
  • Any stage disease

  • Initial, refractory, or relapsed disease. If relapse involves the site to be treated there must be evidence of disease progression

  • Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤ 3

  • Negative pregnancy test done ≤ 7 days prior to registration, for persons of childbearing potential only

  • Provide written informed consent

  • Ability to complete questionnaire(s) by themselves or with assistance

  • Willing to return to enrolling institution for follow-up visits (during the active monitoring phase of the study). Virtual visits can also be considered as an option for applicable items

  • Confirmation from radiation oncologist of suitability to participate in study

Exclusion Criteria:

  • Any of the following:

    • Pregnant women
    • Nursing women
    • Women of childbearing potential who are unwilling to employ adequate contraception
  • T-cell lymphoma

  • Receiving treatment for small and chronic lymphocytic lymphoma

  • Grade 3B follicular lymphoma

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: ARM 1 (reduced dose ISRT)

Patients undergo reduced dose ISRT once daily (excluding weekends): 9 Gy delivered in 3 treatment fractions or 8 Gy in 2 fractions. At physician discretion, patients may receive 10 Gy in 5 fractions. Patients also undergo CT or PET/CT throughout the study. Patients may additionally undergo endoscopy during screening and during follow up.

Ancillary studies

Undergo CT or PET/CT

Andre navn:
  • CT
  • KATT
  • CAT-skanning
  • Beregnet aksial tomografi
  • Datastyrt aksialtomografi
  • Datastyrt tomografi
  • CT skann
  • tomografi
  • Datastyrt aksial tomografi (prosedyre)
  • Datastyrt tomografi (CT) skanning

Undergo PET/CT

Andre navn:
  • Medisinsk bildebehandling, positronemisjonstomografi
  • KJÆLEDYR
  • PET-skanning
  • Positron Emission Tomography Scan
  • Positron-utslippstomografi
  • proton magnetisk resonansspektroskopisk avbildning
  • PT
  • Positronemisjonstomografi (prosedyre)

Undergo endoscopy

Andre navn:
  • ES
  • Endoskopi
  • Endoskopisk undersøkelse

Undergo ISRT in 3 fractions

Andre navn:
  • ISRT
Aktiv komparator: ARM 2 (SOC ISRT)

Patients undergo standard of care (SOC) radiation therapy once daily (excluding weekends): 24 Gy in 12 treatment fractions. Patients also undergo CT or PET/CT throughout the study. Patients may additionally undergo endoscopy during screening and during follow up.

Ancillary studies

Undergo CT or PET/CT

Andre navn:
  • CT
  • KATT
  • CAT-skanning
  • Beregnet aksial tomografi
  • Datastyrt aksialtomografi
  • Datastyrt tomografi
  • CT skann
  • tomografi
  • Datastyrt aksial tomografi (prosedyre)
  • Datastyrt tomografi (CT) skanning

Undergo PET/CT

Andre navn:
  • Medisinsk bildebehandling, positronemisjonstomografi
  • KJÆLEDYR
  • PET-skanning
  • Positron Emission Tomography Scan
  • Positron-utslippstomografi
  • proton magnetisk resonansspektroskopisk avbildning
  • PT
  • Positronemisjonstomografi (prosedyre)

Undergo endoscopy

Andre navn:
  • ES
  • Endoskopi
  • Endoskopisk undersøkelse

Undergo ISRT in 12 fractions

Andre navn:
  • ISRT

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Incidence of grade 2 or higher acute adverse events (AEs)
Tidsramme: Up to 14 days after radiation treatment

AEs will be graded using Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. Acute toxicity will be reported as a proportion calculated as the number of patients with acute toxicity divided by the total number of treatment patients. Treatment cycles are 5 days ±2 days (Arm 1) and 16 days ±2 days (Arm 2).

Up to 14 days after radiation treatment

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Response rate
Tidsramme: Up to 3 months after radiation treatment

Response rate will be defined as the proportion of patients displaying response (complete response or partial response) at 3 months post treatment. Complete response is defined as the disappearance of all signs of cancer in response to treatment. Partial response is defined decrease in the size of target lesions by ≥ 50%, with no increase in the size of any lesion and no appearance of new lesions. Treated patients who do not have a 3-month evaluation will be classified as a non-response. Treatment cycles are 5 days ±2 days (Arm 1) and 16 days ±2 days (Arm 2).

Up to 3 months after radiation treatment
Time to progression rate
Tidsramme: Up to 24 months after radiation treatment

Local control will be defined as the number of days from end of radiation treatment until first local recurrence within 24 months post radiation treatment. Treatment cycles are 5 days ±2 days (Arm 1) and 16 days ±2 days (Arm 2).

Up to 24 months after radiation treatment
Patient reported quality of life
Tidsramme: Up to 3 months after radiation treatment

Patient reported quality of life will be measured using Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) scale, a 13-item questionnaire answered on a scale of 1-5 where 1=Not at all and 5=Very much. Treatment cycles are 5 days ±2 days (Arm 1) and 16 days ±2 days (Arm 2).

Up to 3 months after radiation treatment

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Etterforskere

  • Hovedetterforsker: Brad S. Hoppe, MD, MPH, Mayo Clinic

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

15. mai 2024

Primær fullføring (Antatt)

30. mai 2029

Studiet fullført (Antatt)

30. mai 2031

Datoer for studieregistrering

Først innsendt

23. april 2024

Først innsendt som oppfylte QC-kriteriene

23. april 2024

Først lagt ut (Faktiske)

26. april 2024

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

10. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

6. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Begreper knyttet til denne studien

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

produkt produsert i og eksportert fra USA

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere